Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2021-09-01 00:00:00 ET · period of report 2021-08-31 · accession 0001708138-21-000070 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-09-01 | 2021-08-31 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $555.67 | +1,000 | 26.9K | +4% | +$555.7K |
| D | 2021-09-01 | 2021-08-31 | REGN | Landry Robert E | EVP Fin CFO | F - Tax | $675.03 | -917 | 26.0K | -3% | -$619.0K |
| D | 2021-09-01 | 2021-08-31 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $0.00 | -1,000 | 4,000 | -20% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-31 | M | A | 1,000 | $555.67 | 26,903 | D | — | — | |
| 2 | Common | Common Stock | 2021-08-31 | F | D | 917 | $675.03 | 25,986 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-08-31 | M | D | 1,000 | $0.00 | 4,000 | D | $555.67 · — to 2025-12-16 | 1,000 Common Stock | (F1) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |